TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03046212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: TENS: it was applied in the conventional mode, through four self-adhesive electrodes of size 5x9cm positioned about five centimeters from the edges of the surgical scar, with frequency of 100 Hz and pulse duration of 100μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was it increased during the application time with their permission.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Active exercises of plantar flexion and dorsal flexion of the ankles, flexion and extension of the knees and adduction and abduction of the hips, in both lower limbs. All exercises were performed with the patient in the supine position in the bed, in 10 repetitions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Active exercises of plantar flexion and dorsal flexion of the ankles, flexion and extension of the knees and adduction and abduction of the hips, in both lower limbs. All exercises were performed with the patient in the supine position in the bed, in 10 repetitions.
Study: NCT00170950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2
Description: Benazepril hydrochloride (HCl)/amlodipine besylate 20/5 mg capsules for oral administration once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
Description: Benazepril hydrochloride (HCl)/amlodipine besylate: 40/10 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
Study: NCT03392311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment
Description: The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adipose-derived multipotent mesenchymal stem cells
Description: AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg.
Study: NCT01221597

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AA4500
Description: 2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
Study: NCT00170950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1
Description: Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 20/12.5 mg capsules for oral administration once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2
Description: Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/12.5 mg capsules for oral administration once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
Description: Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/25 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
Study: NCT01221597

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
Study: NCT06264050

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: evalutaion scales
Description: four scales will be administered to whom attend a psychological support group: BDI II (depression); Stai Y2 (trait anxiety); Cope NVI 25 (coping strategies) and Core OM (psychological state)
Study: NCT04439422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short ADHD Intervention
Description: Short, intensive psychological intervention based on CBT and DBT practices

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-help material with limited therapist support
Description: Self-help material from an evidence-based treatment manual for adult ADHD with access to limited therapist support via Internet (control group)
Study: NCT02230072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fetoscopy
Description: The fetoscopic arm is described above. All patients will have a laparotomy, exteriorization of the uterus, and a fetoscopic repair of the fetal open neural tube defect.
Study: NCT04499794

Intervention type: DRUG
Intervention: ALK inhibitor
Description: ALK inhibitor treatment on ALK fusion positive NSCLC patients
Study: NCT01479920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Fluoxetine
Description: Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DCEAS (Hwato®/ Dongbang®)
Description: Six pairs of cranial acupoints are used: Baihui (Du-20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8). All these acupoints are located on the forehead.~Disposable acupuncture needles (Hwato®/ Dongbang®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into acupoints, on which low- and high-frequency alternating electrical stimulation with continuous waves is conducted for 30 min. The intensity is adjusted to a level at which patients feel comfortable.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: n-CEA (Strietberger®)
Description: Streitberger's acupuncture needles will be applied on the same acupoints, with the same electrical stimulation parameters, except that the needles only adhere to the skin instead of insertion.
Study: NCT02127164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veraflo device, Dakin's solution
Description: Veraflo device will be installed on the wound to create negative pressure after surgery. Dakin's solution will be instilled through this device into the wound at the regular intervals.
Study: NCT03643952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin for Injection
Description: Once daily administration of 5, 7, 9, 10, or 12 mg/kg intravenous (IV) daptomycin infused with 25-50 mL saline over 30-60 minutes depending upon infection type and age level.
Study: NCT01598480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flamazine
Description: Silver sulfadiazine cream

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCT Antimicrobial Dressing
Description: Activated carbon fiber impregnated with silver particles
Study: NCT03942250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGE pro dressing
Description: REGE pro is a dressing of dried human amniotic membrane sterilized by gamma radiation
Study: NCT04134442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Liposome Injection
Description: 1. Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist)~2. Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: 1. Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist)~2. Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 20ml 0.5% bupivacaine and epinephrine 1:200,000.
Study: NCT02939404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure
Description: 23.25 hours inside respiratory chamber with the temperature set to19°C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure
Description: 23.25 hours inside respiratory chamber with the temperature set to19°C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal temperature
Description: 23.25 hours inside respiratory chamber with the temperature set to 24°C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal temperature
Description: 23.25 hours inside respiratory chamber with the temperature set to 24°C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal temperature
Description: 23.25 hours inside respiratory chamber with the temperature set to 24°C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fixed diet
Description: A diet that matches the participant's caloric needs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fixed diet
Description: A diet that matches the participant's caloric needs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum diet
Description: Participants can eat as much as they want

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum diet
Description: Participants can eat as much as they want

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Participants do not eat for 12 hours before and 24 hours in chamber
Study: NCT02500992

Intervention type: PROCEDURE
Intervention: Transrectal sigmoidectomy
Study: NCT03455972

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 and anti-BCMA CAR
Description: Participants will get auto-HSCT. Hematopoietic reconstitution after auto-HSCT, participants will get the anti-CD19 CAR T cells (1×10e+7/kg on d0) and anti-BCMA CAR T cells as split-dose (total 5×10e+7/kg, 40% on d1 and 60% on d2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunomodulatory drugs
Description: Maintenance therapy
Study: NCT03579459

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Clostridium difficile vaccine
Description: Toxoid based Clostridium difficile vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Clostridium difficile vaccine
Description: Toxoid based Clostridium difficile vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Clostridium difficile vaccine
Description: Toxoid based Clostridium difficile vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Normal saline solution
Study: NCT00742703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mineralized water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low mineralized water
Study: NCT05709730

Intervention type: DIAGNOSTIC_TEST
Intervention: HPV genotyping
Description: HPV genotyping of samples classified that were positive for other HPV
Study: NCT05130112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula and nasal cannula
Description: HFNC was administered using the MyAIRVO 2 device (Fisher \& Paykel Healthcare, Auckland, New Zealand), which provides humidification and high-flow medical gas through an Optiflow NC interface (Fisher \& Paykel Healthcare, Auckland, New Zealand) is administered for 10 min..~NC is administered for 10 min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula and nasal cannula
Description: HFNC was administered using the MyAIRVO 2 device (Fisher \& Paykel Healthcare, Auckland, New Zealand), which provides humidification and high-flow medical gas through an Optiflow NC interface (Fisher \& Paykel Healthcare, Auckland, New Zealand) is administered for 10 min..~NC is administered for 10 min.
Study: NCT06535360

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet transfusion
Description: platelet administration through intravenous access

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet transfusion
Description: platelet administration through intravenous access
Study: NCT02362698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electro-acupuncture
Description: 13points were selected including he-gu(LI4), nei-guan(PC6), tai-chong(LR3) and san-yin-jiao(SP6) from both sides, bai-hui(GV20) and si-shen-cong(EX-HN1) from head.~HANS-200A acupoints stimulator, which had two output channels, was connected to some selected points. Dilatational wave was adopted in this research, the frequency of rarefaction wave was 2 hertz and condensation wave was 100 hertz, with a waviness width of 0.3ms. Switched the stimulator on after connected the poles to the needles, adjusted the intensity of output gradually from 0 milliampere to the extent of subject's maximum tolerance. Then needles would be remained on the body for half an hour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psychological intervention
Description: Cognitive behavioral therapy was adopted by national accredited professional psychologist, in the form of team work and individual counseling, aim to help IA participants to understand their deviant behaviors, correct unhealthy cognitive states and eventually retrieve normal life style.
Study: NCT03862404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-epinephrine
Description: See previous description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: See previous descreption
Study: NCT01300130

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low docosahexaenoic acid formula

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: medium docosahexaenoic acid formula

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high docosahexaenoic acid formula

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: breast milk
Description: a non randomized group of breast milk fed infants was included
Study: NCT00121238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV
Study: NCT02521090

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFRBi-Armed Autologous T Cells
Description: Given IT and IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00349089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22~Comparator:~Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29 Cisplatin 50 mg/m2 d1, 8; q d29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22~Comparator:~Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29 Cisplatin 50 mg/m2 d1, 8; q d29

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29
Study: NCT05369650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride, Injectable
Description: The lidocaine group 1, 1.5 and 2 groups were injected with 1% lidocaine 1.5mg/kg (ideal body weight, 10min infusion) after anesthesia induction, respectively, and then continued to infuse 1% lidocaine. 1mg/kg.h, 1.5mg/kg.h, 2mg/kg.h (ideal body weight) until the end of the operation, and a patient-controlled intravenous analgesia (PCIA) pump containing lidocaine (PCIA) 0.3-1.5mg/kg after surgery. h to 72h after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride, Injectable
Description: The lidocaine group 1, 1.5 and 2 groups were injected with 1% lidocaine 1.5mg/kg (ideal body weight, 10min infusion) after anesthesia induction, respectively, and then continued to infuse 1% lidocaine. 1mg/kg.h, 1.5mg/kg.h, 2mg/kg.h (ideal body weight) until the end of the operation, and a patient-controlled intravenous analgesia (PCIA) pump containing lidocaine (PCIA) 0.3-1.5mg/kg after surgery. h to 72h after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride, Injectable
Description: The lidocaine group 1, 1.5 and 2 groups were injected with 1% lidocaine 1.5mg/kg (ideal body weight, 10min infusion) after anesthesia induction, respectively, and then continued to infuse 1% lidocaine. 1mg/kg.h, 1.5mg/kg.h, 2mg/kg.h (ideal body weight) until the end of the operation, and a patient-controlled intravenous analgesia (PCIA) pump containing lidocaine (PCIA) 0.3-1.5mg/kg after surgery. h to 72h after surgery.
Study: NCT02898974

Intervention type: BEHAVIORAL
Intervention: Medical Marijuana
Description: To investigate the effects of medical marijuana usage on physical function we will employ an observational case-control design
Study: NCT00712842

Intervention type: OTHER
Intervention: Ocular blood flow measurements
Description: non-invasive haemodynamic measurements of retinal vessel diameters and laser Doppler velocimetry
Study: NCT04229706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Xiang Ju Ru Pi Ning capsule
Description: xingjurupining capsule,8 capsule,tid,3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Xiang Ju Ru Pi Ning capsule
Description: xiangjurupining capsule,4 capsules , and xiangjurupining capsule placebo,4 capsules,tid,3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xiang Ju Ru Pi Ning capsule placebo
Description: xiangjurupining capsule,8 capsule,tid,3 months.
Study: NCT01426191

Intervention type: DRUG
Intervention: xinzhijun
Description: durg:Cefotaxime sodium and sulbactam sodium for injection(2:1)~1.5-3.0g,iv,bid or tid for 5-12 days;~Serious infections:1.0-1.5g,iv,tid or qid for 5-12 days
Study: NCT03043664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: Somatuline depot (lanreotide) 90 mg SQ every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Keytruda (pembrolizumab) 200 mg IV every 3 weeks
Study: NCT01973933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Pyrimethamine
Study: NCT02868060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Study: NCT01540851

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care Navigator
Description: Subjects assigned to the Care Navigator intervention group will receive 10 calls from a care navigator after discharge from the hospital for 5 months after their total knee replacement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Post-Operative TKA Care
Description: Subjects assigned to the Standard Post-Operative TKA Care group will receive the current standard of care for post-operative care
Study: NCT03842657

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: anticoagulation of the dialysis circuit
Description: Each patient included in this study will receive two heparin-free dialysis sessions with heparin-grafted membrane (control group) or RCA with calcium-free citrate-containing dialysate and calcium reinjection according to the ionic dialysance (experimental group), alternatively

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: anticoagulation of the dialysis circuit
Description: Each patient included in this study will receive two heparin-free dialysis sessions with heparin-grafted membrane (control group) or RCA with calcium-free citrate-containing dialysate and calcium reinjection according to the ionic dialysance (experimental group), alternatively
Study: NCT01507220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine sulfate
Description: Patients in this group will receive IV morphine sulfate (or Sponsor-approved equivalent) via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour. All morphine sulfate (Group 1) patients will receive the same opioid in their PCA pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine liposome extended-release injectable suspension
Description: Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed.
Study: NCT04288570

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suture anchor socket creation with punch
Description: suture anchor socket creation with punch

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suture anchor socket creation with drill
Description: suture anchor socket creation with drill